LIMITED OFFER
Save 50% on book bundles
Immediately download your ebook while waiting for your print delivery. No promo code needed.
Insulin
Deficiency, Excess and Resistance in Human Disease
- 1st Edition - January 18, 2024
- Editor: Andrew J. Krentz
- Language: English
- Paperback ISBN:9 7 8 - 0 - 3 2 3 - 9 1 7 0 7 - 0
- eBook ISBN:9 7 8 - 0 - 3 2 3 - 9 8 5 6 9 - 7
Insulin: Deficiency, Excess and Resistance in Human Disease provides an overview of the role of insulin in the pathogenesis of prevalent non-communicable diseases such as obesit… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quoteInsulin: Deficiency, Excess and Resistance in Human Disease provides an overview of the role of insulin in the pathogenesis of prevalent non-communicable diseases such as obesity, type 2 diabetes, cardiovascular disease, and cancer, along with a comprehensive review of insulin replacement therapies and novel cardioprotective and insulin-sensitizing drugs. Notable advances in precision diagnosis and therapy for single gene subtypes of diabetes in recent years are also discussed.
The discovery of insulin and its lifesaving introduction into clinical practice is one of the most celebrated accomplishments of medical science. However, despite decades of progress and major technical advances, the goal of providing insulin replacement therapy that truly mimics normal physiology remains elusive.
The discovery of insulin and its lifesaving introduction into clinical practice is one of the most celebrated accomplishments of medical science. However, despite decades of progress and major technical advances, the goal of providing insulin replacement therapy that truly mimics normal physiology remains elusive.
- Presents etiology and pathogenesis of insulin deficiency, insulin excess and insulin resistance in a wide spectrum of human diseases, ranging from rare to highly prevalent disorders
- Discusses the latest developments in the diagnosis and management of insulin-related disorders and prospects for future developments
- Explores the increasingly complex pharmacological landscape that comprises a bewildering range of drug-based interventions
Basic and clinical researchers involved in the management of patients with insulin-related disorders, endocrinologists and diabetologists.
- Cover image
- Title page
- Table of Contents
- Copyright
- List of contributors
- Foreword
- Preface
- Section 1: Normal physiology: insulin secretion and insulin action
- Chapter 1. Insulin biosynthesis and release in health and disease
- Abstract
- Insulin biosynthesis
- Insulin release
- Concluding remarks
- References
- Chapter 2. Classic metabolic actions of insulin in humans: from physiology to disease and novel pharmacotherapeutics
- Abstract
- Introduction
- Insulin structure and synthesis
- Physiological actions of action
- Clinical states of acute metabolic decompensation associated with insulin deficiency
- References
- Chapter 3. Nonclassic effects of insulin: physiological actions on the vascular tissues and pathophysiological contributions to atherogenesis, mitogenesis, and restenosis
- Abstract
- Introduction
- Overview of insulin and cardiovascular disease
- Effects of insulin on the vascular tissues and atherogenesis
- Effects on insulin on blood flow and the vascular wall
- Effects on endothelial cells and selective insulin resistance
- Effects on vascular smooth muscle cells
- Effects on thrombosis
- Summary
- Acknowledgments
- References
- Section 2: Role of insulin in human disease
- Chapter 4. Type 1 diabetes pathogenesis: lessons learned and remaining questions
- Abstract
- Clinical scenario
- Role of genetics in the pathogenesis of type 1 diabetes
- References
- Chapter 5. Insulin therapy: a century of continuing progress
- Abstract
- Introduction
- The long way to insulin therapy
- Evolution of insulin therapy over 100 years
- Insulin analogs
- Conclusions
- Acknowledgments
- Conflict of interest
- References
- Chapter 6. Treatment and prevention of type 1 diabetes in the 21st century
- Abstract
- Introduction
- Prediction
- Prevention of decline in β-cell function
- Contemporary management of type 1 diabetes
- Replacement of β cells
- References
- Chapter 7. Differentiation of diabetes by pathophysiology: focus on insulin deficiency versus insulin resistance
- Abstract
- Introduction
- Type 2 diabetes
- Type 1 diabetes
- Diagnosis of MODY
- Treatment of MODY
- Other approaches to classification
- Subclassification of people at risk for type 2 diabetes
- Ethnicity considerations
- Summary and conclusions
- References
- Section 2b: Syndromes of insulin excess
- Chapter 8. Congenital hyperinsulinism
- Abstract
- Introduction
- Epidemiology
- Pathophysiology
- Perinatal stress-induced hyperinsulinism
- Congenital hyperinsulinism
- Syndromic hyperinsulinism
- Diagnosis
- Management
- Outcomes
- Conclusion
- References
- Chapter 9. Hypoglycemic disorders in adults
- Abstract
- Clinical manifestations
- Management
- Postgastric bypass hypoglycemia
- NIPHS
- Recurrence, survival, and surveillance
- Conclusion
- References
- Section 2c: Insulin resistance in human disease
- Chapter 10. Obesity and insulin resistance: pathophysiology guiding precision therapy
- Abstract
- Introduction
- Insulin resistance: substrates and genetics
- Effect of adiposity on hepatic and extrahepatic insulin action
- Insulin suppression of lipolysis
- Insulin suppression of glycogenolysis and gluconeogenesis
- Splanchnic glucose uptake and splanchnic glucose production
- Nocturnal regulation of glucose homeostasis in type 2 diabetes
- Therapeutic approaches
- Summary and conclusions
- References
- Chapter 11. The cardiometabolic syndrome and vascular disease: pivotal role of insulin
- Abstract
- Introduction
- Pathophysiology of atherosclerosis
- Role of insulin resistance in atherosclerosis
- Role of insulin resistance and hyperglycemia in microvascular disease
- Genetic and epigenetic associations with insulin resistance and cardiovascular disease
- Clinical features of cardiometabolic syndrome and insulin resistance
- Prevention of diabetes and ASCVD
- Medical therapies for primary prevention and treatment of metabolic syndrome components: a brief overview
- Treatment of type 2 diabetes mellitus
- Conclusions
- References
- Chapter 12. Insulin resistance, hyperinsulinemia, and cancer: pathogenic considerations and therapeutic opportunities
- Abstract
- Introduction
- Visceral adipose tissue, inflammation, and insulin resistance
- Insulin resistance, hyperinsulinemia and cancer: epidemiologic links
- Insulin resistance, hyperinsulinemia, and cancer: mechanisms
- Therapeutic considerations
- Summary
- Funding
- Conflict of interest
- References
- Chapter 13. Insulin and neurodegenerative diseases
- Abstract
- Introduction
- The brain is an insulin-sensitive organ
- Receptor expression in the brain
- Insulin production and transport across the blood-brain barrier
- Insulin and insulin-like signaling in the brain
- Control of cellular metabolism by insulin
- Abnormalities associated with dysregulated insulin/IGF-1 signaling
- AD brains show insulin and IGF1 resistance
- Sources of brain insulin resistance in neurodegeneration
- Diabetes interventions for the prevention or treatment of neurodegeneration
- Conclusions
- References
- Chapter 14. Nonpharmacological, pharmacological, and surgical options for obesity-related cardiometabolic disorders
- Abstract
- Background
- Nonpharmacological approaches
- Pharmacological approaches
- Surgical approaches
- Clinical impact of weight reduction from obesity surgery
- Conclusion
- References
- Chapter 15. Syndromes of severe insulin resistance: lessons from nature
- Abstract
- Introduction
- Syndromes of severe insulin resistance
- Conclusions
- References
- Index
- No. of pages: 444
- Language: English
- Edition: 1
- Published: January 18, 2024
- Imprint: Academic Press
- Paperback ISBN: 9780323917070
- eBook ISBN: 9780323985697
AK
Andrew J. Krentz
Andrew Krentz has four decades of clinical and translational research experience in metabolic, endocrine and related cardiovascular disorders.
His expertise in the life sciences includes preclinical and early-phase clinical drug development; he has personally contributed translational medical innovations to endocrinology clinical practice. He is actively involved in projects focused on precision diagnostics and therapeutics, digital healthcare, and healthy longevity that bridge the academic-industry spaces.
Beyond his expertise in diabetes and endocrinology, he is accredited as a clinical specialist by the European Society for Hypertension and is a member of the Medical, Scientific & Research Committee of Heart UK. He is President-Elect of the Vascular, Lipid & Metabolism section of the Royal Society of Medicine as well as being a member of the European Group for the Study of Insulin Resistance (EGIR) and the Diabetes & Cardiovascular Study Group of the European Association for the Study of Diabetes (EASD).
He has authored more than 200 scientific publications and founded the journal Cardiovascular Endocrinology & Metabolism and serves as Editor-in-Chief.
Affiliations and expertise
Visiting Professor, Institute of Cardiovascular and Metabolic Research, University of Reading, UKRead Insulin on ScienceDirect